Keywords: phase, iii, data, genentech/xoma, xanelim, show, efficacy

Phase III data with Genentech/Xoma's Xanelim show efficacy in psoriasis

Article | 02 August 2001

Print This

Genentech and Xoma have reported data from a second Phase III trial oftheir humanized anti-CD11 monoclonal antibody Xanelim (efalizumab) at ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in